Ustariz GCR

Language: Spanish
References: 26
Page:
PDF size: 38.75 Kb.

ABSTRACT

Interferon a (IFN-a), is used together with other antivirals in the treatment of chronic hepatitis C. Autoimmune disorders have been described during its use, particularly thyroid diseases and type 1 diabetes mellitus (DM1), among others. We report the case of a patient with chronic hepatitis C, showing severe symptoms of coma, metabolic ketoacidosis, hyperglycemia and dehydration after 6 months of treatment with IFN-aand ribavirin. The beginning of a secondary DM 1 at the administration of IFN-a was diagnosed. There was no personal or family history of genetic factors predisposing to the development of this disease. The patient was treated in an Emergency Medical Unit (MEU) where medication to control its manifestations was received. Administration of IFN-a was suspended and the ambulatory treatment is maintained, applying insulin in fractional doses adjusted to blood glucose values.

REFERENCES

1. Vinagre I, Rigla M, Torres X, Enriquez J, Corcoy R. Aparición de diabetes mellitus tipo 1 durante el tratamiento con interferón alfa: dos casos clínicos. Endocrinol Nutr 2010; 57(8):393-5.

2. Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002; 47(7): 1649-54.

3. Yuan-Yuan L, Bing-Yin S, Hui G. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B. World J Gastroenterol 2008 August 7; 14(29):4713-5.

4. Piquer S, Hernandez C, Enriquez J, Ross A, Esteban JI, Genesca J, Bonifacio E, Puig- Domingo M, Simo R. Islet cells and Thyroid antibody prevalence in patientes with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 2001; 137(1): 38-42.

5. Bottazo GF, Dean BM, Mc Nally GM, Mc Kay EH, Swift PGF, Gamble DR. In situ characterisation of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetes mellitus. N Engl J Med 1985 Aug: 313(6): 353-60.

6. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000, 23(8): 1177-81.

7. Seifarth C, Benninger J, Bohm BO, Wiest-Ladenburger U, Hahn EG, Hensen J. Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C. Z Gastroenterol 1999 Mar; 37(3):235-9.

8. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulindependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998 Mar; 28(3):514-7.

9. Eibl N, Gschwantier M, Ferenci P, Elbl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol 2001 Mar;13(3): 295-8.

10. Atkinson Ma, Elsenbarth GS. Type 1 diabetes mellitus: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358(9277): 221-9.

11. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon on insulinsecreting beta-cells in type 1 diabetes mellitus. Lancet 1987: 2(8573): 1423-7.

12. Koivisto VA, Peklonen R, Cantal K. Effect of interferon on glucosa tolerance and insulin sensitivity. Diabetes 1989; 38(5): 641-7.

13. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T: Onset of diabetes with high titer anti-GAD antibody after INF therapy for chronic hepatitis. Diabetes Res Clin Pract 1995; 30(3):237-41.

14. Fattovich G, Betterle C, Brollo L. Autoantibodies during alpha-IFN therapy for chronic hepatitis B. J Med Virol 1991;34(2): 132-5.

15. Todd JA, Bell JI, Mc Devitt HO. HLA-DQB gene contributes to susceptibility and resistence to insulin-dependent diabetes mellitus. Nature 1987; 329:599-604.

16. Konrad T, Vicini P, Zeuzem S, Toffolo G, Briem D, Lormann J, et al. Interferonalpha improves glucose tolerance in diabetic and non-diabetic patients with HCVinduced liver disease. Exp Clin Endocrinol Diabetes 1999; 107(6): 343-9.

17. Imano E, Kanda T, Ishigami Y. Interferon incidences insulin resistance in patients with chronic hepatitis C. J Hepatol 1998; 28: 189-93.

18. Gray H, Wreighiit T, Stratton I M, Alexander G J, Turner R C, O Rahilly S. High prevalence of hepatitis C infection in Afro- Caribean patients type 2 diabetes and normal function tests. Diabet Med 1993; 12: 244-9.

19. Everhart J A. Confluences of epidemics. Does hepatitis C cause type 2 diabetes. Hepatology 2001, 33: 762-3

20. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and hashitoxicosis in a patient treatment with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-4.

21. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Internal Med 1996 Sep; 125(6): 521.

22. Fabris P, Betterle C, Floreani A, Gregio NA, De Lazzari F, Naccarato R, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992 Aug ; 340(8818): 548.

23. Recasens M, Aguilera E, Ampurdanes S, Sanchez Tapias JM, Simó O, Casamitjana R, et al. Abrupt onset of diabetes during interferon alpha therapy in patients with chronic hepatitis C. Diabetes Med 2001 Sept; 18(9): 764-7.

24. Betterle P, Floreani A, Tisitti G, Vergani D, de Llala F, Betterle C. Review article: Type 1 diabetes mellitus in patients with chronic hepatitis C before interferon therapy. Aliment Pharmacol Ther 2003; 18(6): 549-58.

25. Masan AL, Lam JV, Hoang N. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29:329-33.

26. Van der Werf N, Kroese FG, Rozing J. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 169-83.